Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1385924rdf:typepubmed:Citationlld:pubmed
pubmed-article:1385924lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:1385924lifeskim:mentionsumls-concept:C0025255lld:lifeskim
pubmed-article:1385924lifeskim:mentionsumls-concept:C0005821lld:lifeskim
pubmed-article:1385924lifeskim:mentionsumls-concept:C0040057lld:lifeskim
pubmed-article:1385924lifeskim:mentionsumls-concept:C0023688lld:lifeskim
pubmed-article:1385924lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:1385924pubmed:dateCreated1992-8-20lld:pubmed
pubmed-article:1385924pubmed:abstractText[3H]-BAY U 3405 was used to characterize the pH-dependency of the binding of various ligands to the TXA2/PGH2-receptor of human platelet membranes. Maximum binding of [3H]-BAY U 3405 is achieved at pH 5.8. In inhibition studies the ligands Daltroban, CTA2, and U 46619 also show a higher affinity at pH 5.8 compared to pH 7.4. In contrast, the ligands I-PTA-OH and GR 32191 have a higher affinity at pH 7.4. No difference is seen with SQ 29548. The ligands I-PTA-OH, GR 32191, and SQ 29548 have a second protonable group in common, which is thought to be the reason for the different pH-dependent binding.lld:pubmed
pubmed-article:1385924pubmed:languageenglld:pubmed
pubmed-article:1385924pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1385924pubmed:citationSubsetIMlld:pubmed
pubmed-article:1385924pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1385924pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1385924pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1385924pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1385924pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1385924pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1385924pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1385924pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1385924pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1385924pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1385924pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1385924pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1385924pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1385924pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1385924pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1385924pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1385924pubmed:statusMEDLINElld:pubmed
pubmed-article:1385924pubmed:issn0379-0363lld:pubmed
pubmed-article:1385924pubmed:authorpubmed-author:GrossRRlld:pubmed
pubmed-article:1385924pubmed:authorpubmed-author:DellwegHHlld:pubmed
pubmed-article:1385924pubmed:authorpubmed-author:PerzbornEElld:pubmed
pubmed-article:1385924pubmed:authorpubmed-author:TheisJ GJGlld:pubmed
pubmed-article:1385924pubmed:issnTypePrintlld:pubmed
pubmed-article:1385924pubmed:volume37lld:pubmed
pubmed-article:1385924pubmed:ownerNLMlld:pubmed
pubmed-article:1385924pubmed:authorsCompleteYlld:pubmed
pubmed-article:1385924pubmed:pagination222-7lld:pubmed
pubmed-article:1385924pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1385924pubmed:meshHeadingpubmed-meshheading:1385924-...lld:pubmed
pubmed-article:1385924pubmed:meshHeadingpubmed-meshheading:1385924-...lld:pubmed
pubmed-article:1385924pubmed:meshHeadingpubmed-meshheading:1385924-...lld:pubmed
pubmed-article:1385924pubmed:meshHeadingpubmed-meshheading:1385924-...lld:pubmed
pubmed-article:1385924pubmed:meshHeadingpubmed-meshheading:1385924-...lld:pubmed
pubmed-article:1385924pubmed:meshHeadingpubmed-meshheading:1385924-...lld:pubmed
pubmed-article:1385924pubmed:meshHeadingpubmed-meshheading:1385924-...lld:pubmed
pubmed-article:1385924pubmed:meshHeadingpubmed-meshheading:1385924-...lld:pubmed
pubmed-article:1385924pubmed:meshHeadingpubmed-meshheading:1385924-...lld:pubmed
pubmed-article:1385924pubmed:meshHeadingpubmed-meshheading:1385924-...lld:pubmed
pubmed-article:1385924pubmed:meshHeadingpubmed-meshheading:1385924-...lld:pubmed
pubmed-article:1385924pubmed:meshHeadingpubmed-meshheading:1385924-...lld:pubmed
pubmed-article:1385924pubmed:meshHeadingpubmed-meshheading:1385924-...lld:pubmed
pubmed-article:1385924pubmed:meshHeadingpubmed-meshheading:1385924-...lld:pubmed
pubmed-article:1385924pubmed:meshHeadingpubmed-meshheading:1385924-...lld:pubmed
pubmed-article:1385924pubmed:meshHeadingpubmed-meshheading:1385924-...lld:pubmed
pubmed-article:1385924pubmed:meshHeadingpubmed-meshheading:1385924-...lld:pubmed
pubmed-article:1385924pubmed:meshHeadingpubmed-meshheading:1385924-...lld:pubmed
pubmed-article:1385924pubmed:meshHeadingpubmed-meshheading:1385924-...lld:pubmed
pubmed-article:1385924pubmed:year1992lld:pubmed
pubmed-article:1385924pubmed:articleTitlepH-dependent binding of the TXA2/PGH2-receptor of human platelet membranes to various ligands.lld:pubmed
pubmed-article:1385924pubmed:affiliationInstitut für Herz/Kreislauf- und Artheroskleroseforschung, Bayer AG, Wuppertal, Germany.lld:pubmed
pubmed-article:1385924pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1385924pubmed:publicationTypeIn Vitrolld:pubmed